Rachel B. Issaka

Rachel B. Issaka

Auto-generated profile, based on publicly available information

Rachel B. Issaka

Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Center, Seattle, Washington, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2024 in New England Journal of Medicine
Verified
Journal Article
Closed access
DCDaniel C. Chung
Daniel C. Chung
DGDarrell M. Gray
Darrell M. Gray
HSHarminder Singh
Harminder Singh
RIRachel B. Issaka
Rachel B. Issaka
VRVictoria M. Raymond
Victoria M. Raymond
WGWilliam M. Grady
William M. Grady
Colorectal cancer is the third most diagnosed cancer in adults in the United States. Early detection could prevent more than 90% of colorectal cancer-related deaths, yet more than one third of the screening-eligible population is not up to date with screening despite multiple available tests. A blood-based test has the potential to improve screening adherence, detect colorectal cancer earlier, and reduce colorectal cancer-related mortality. We assessed the performance characteristics of a cell-free DNA (cfDNA) blood-based test in a population eligible for colorectal cancer screening. The coprimary outcomes were sensitivity for colorectal cancer and specificity for advanced neoplasia (colorectal cancer or advanced precancerous lesions) relative to screening colonoscopy. The secondary outcome was sensitivity to detect advanced precancerous lesions. The clinical validation cohort included 10,258 persons, 7861 of whom met eligibility criteria and were evaluable. A total of 83.1% of the participants with colorectal cancer detected by colonoscopy had a positive cfDNA test and 16.9% had a negative test, which indicates a sensitivity of the cfDNA test for detection of colorectal cancer of 83.1% (95% confidence interval [CI], 72.2 to 90.3). Sensitivity for stage I, II, or III colorectal cancer was 87.5% (95% CI, 75.3 to 94.1), and sensitivity for advanced precancerous lesions was 13.2% (95% CI, 11.3 to 15.3). A total of 89.6% of the participants without any advanced colorectal neoplasia (colorectal cancer or advanced precancerous lesions) identified on colonoscopy had a negative cfDNA blood-based test, whereas 10.4% had a positive cfDNA blood-based test, which indicates a specificity for any advanced neoplasia of 89.6% (95% CI, 88.8 to 90.3). Specificity for negative colonoscopy (no colorectal cancer, advanced precancerous lesions, or nonadvanced precancerous lesions) was 89.9% (95% CI, 89.0 to 90.7). In an average-risk screening population, this cfDNA blood-based test had 83% sensitivity for colorectal cancer, 90% specificity for advanced neoplasia, and 13% sensitivity for advanced precancerous lesions. (Funded by Guardant Health; ECLIPSE ClinicalTrials.gov number, NCT04136002.).

1 January 2019 in Preventive Medicine
Verified
Journal Article
Closed access
RIRachel B. Issaka
Rachel B. Issaka
PAPatrick Avila
Patrick Avila
EWEvans Whitaker
Evans Whitaker
SBStephen Bent
Stephen Bent
MSMa Somsouk
Ma Somsouk

21 September 2023 in Gastroenterology
Verified
Journal Article
Open access
RIRachel B. Issaka
Rachel B. Issaka
ACAndrew T. Chan
Andrew T. Chan
SGSamir Gupta
Samir Gupta
Since the early 2000s, there has been a rapid decline in colorectal cancer (CRC) mortality, due in large part to screening and removal of precancerous polyps. Despite these improvements, CRC remains the second leading cause of cancer deaths in the United States, with approximately 53,000 deaths projected in 2023. The aim of this American Gastroenterological Association (AGA) Clinical Practice Update Expert Review was to describe how individuals should be risk-stratified for CRC screening and post-polypectomy surveillance and to highlight opportunities for future research to fill gaps in the existing literature. This Expert Review was commissioned and approved by the American Gastroenterological Association (AGA) Institute Clinical Practice Updates Committee (CPUC) and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the CPUC and external peer review through standard procedures of Gastroenterology. These Best Practice Advice statements were drawn from a review of the published literature and from expert opinion. Because systematic reviews were not performed, these Best Practice Advice statements do not carry formal ratings regarding the quality of evidence or strength of the presented considerations. Best Practice Advice Statements BEST PRACTICE ADVICE 1: All individuals with a first-degree relative (defined as a parent, sibling, or child) who was diagnosed with CRC, particularly before the age of 50 years, should be considered at increased risk for CRC. BEST PRACTICE ADVICE 2: All individuals without a personal history of CRC, inflammatory bowel disease, hereditary CRC syndromes, other CRC predisposing conditions, or a family history of CRC should be considered at average risk for CRC. BEST PRACTICE ADVICE 3: Individuals at average risk for CRC should initiate screening at age 45 years and individuals at increased risk for CRC due to having a first-degree relative with CRC should initiate screening 10 years before the age at diagnosis of the youngest affected relative or age 40 years, whichever is earlier. BEST PRACTICE ADVICE 4: Risk stratification for initiation of CRC screening should be based on an individual's age, a known or suspected predisposing hereditary CRC syndrome, and/or a family history of CRC. BEST PRACTICE ADVICE 5: The decision to continue CRC screening in individuals older than 75 years should be individualized, based on an assessment of risks, benefits, screening history, and comorbidities. BEST PRACTICE ADVICE 6: Screening options for individuals at average risk for CRC should include colonoscopy, fecal immunochemical test, flexible sigmoidoscopy plus fecal immunochemical test, multitarget stool DNA fecal immunochemical test, and computed tomography colonography, based on availability and individual preference. BEST PRACTICE ADVICE 7: Colonoscopy should be the screening strategy used for individuals at increased CRC risk. BEST PRACTICE ADVICE 8: The decision to continue post-polypectomy surveillance for individuals older than 75 years should be individualized, based on an assessment of risks, benefits, and comorbidities. BEST PRACTICE ADVICE 9: Risk-stratification tools for CRC screening and post-polypectomy surveillance that emerge from research should be examined for real-world effectiveness and cost-effectiveness in diverse populations (eg, by race, ethnicity, sex, and other sociodemographic factors associated with disparities in CRC outcomes) before widespread implementation.

1 April 2021 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
RIRachel B. Issaka
Rachel B. Issaka
PTPreston Taylor
Preston Taylor
ABAnand Baxi
Anand Baxi
JIJohn M. Inadomi
John M. Inadomi
SRScott D. Ramsey
Scott D. Ramsey
JRJoshua Roth
Joshua Roth
Colorectal cancer (CRC) is the second-leading cause of cancer death in the US.1 Despite clear evidence that screening by colonoscopy and stool-based tests is cost-effective2 and saves lives,3,4 screening remains underutilized.5 In the US, only 67% of adults between the ages of 50 and 75 are up to date with CRC screening,6 and in Federally Qualified Health Centers, the largest providers of care to underinsured and uninsured individuals, only 44% of the population is up to date.7 Both estimates fall short of the National Colorectal Roundtable goal of achieving 80% adherence to CRC screening.8

12 May 2020 in JAMA Health Forum
Verified
Journal Article
Closed access
RIRachel B. Issaka
Rachel B. Issaka
MSMa Somsouk
Ma Somsouk
On March 18, the Centers for Medicare & Medicaid Services issued guidance that all nonurgent surgeries and medical procedures be delayed during the COVID-19

2 August 2021 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
RIRachel B. Issaka
Rachel B. Issaka
ABAri Bell-Brown
Ari Bell-Brown
CSCyndy Snyder
Cyndy Snyder
DADana L. Atkins
Dana L. Atkins
LCLisa Chew
Lisa Chew
SRScott D. Ramsey
Scott D. Ramsey
There is clear evidence that screening for colorectal cancer (CRC) by stool-based tests is cost-effective1 and saves lives2; however, screening remains underused, especially among members of racial/ethnic minority groups and low-income populations.3 In safety net health care settings and federally qualified health centers (FQHCs) (eTable in the Supplement), in which many medically underserved populations receive care, CRC screening improves when a fecal immunochemical test (FIT) is offered alongside colonoscopy.4 Additionally, owing to patient preference and limited resources,5 FIT has become a cornerstone for CRC screening in these settings. Among patients with an abnormal FIT result, the estimated CRC prevalence is 3.4%6 and a missed or delayed diagnostic colonoscopy is associated with increased CRC mortality.7,8 Despite these concerns, the proportion of patients with an abnormal FIT result who complete a diagnostic colonoscopy rarely exceeds 50% in most safety net systems and FQHCs.9-11